Elanco Animal Health (ELAN) Expected to Announce Quarterly Earnings on Wednesday

Elanco Animal Health (NYSE:ELAN - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $1.17 billion for the quarter.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the business earned $0.08 EPS. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Stock Performance

ELAN traded up $0.28 during midday trading on Friday, hitting $9.75. 3,509,607 shares of the company were exchanged, compared to its average volume of 4,948,857. The company's 50 day simple moving average is $9.89 and its 200 day simple moving average is $11.48. The firm has a market capitalization of $4.84 billion, a price-to-earnings ratio of 24.36, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ELAN shares. Piper Sandler cut their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Morgan Stanley cut their price objective on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Barclays reduced their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus reduced their price target on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Hold" and a consensus target price of $14.67.

Insider Activity

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $10.90 per share, with a total value of $109,000.00. Following the completion of the purchase, the director now directly owns 101,459 shares of the company's stock, valued at approximately $1,105,903.10. This trade represents a 10.93 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.89% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.